Proteomic analysis identifies dysregulated proteins and associated molecular pathways in a cohort of gallbladder cancer patients of African ancestry.
Gallbladder cancer
Gallstone disease
Molecular pathways
Proteins
SWATH-MS
Journal
Clinical proteomics
ISSN: 1542-6416
Titre abrégé: Clin Proteomics
Pays: England
ID NLM: 101184586
Informations de publication
Date de publication:
01 Mar 2023
01 Mar 2023
Historique:
received:
05
09
2022
accepted:
23
02
2023
entrez:
1
3
2023
pubmed:
2
3
2023
medline:
2
3
2023
Statut:
epublish
Résumé
Gallbladder cancer (GBC) is a lethal cancer with a poor prognosis. The lack of specific and sensitive biomarkers results in delayed diagnosis with most patients presenting at late stages of the disease. Furthermore, there is little known about the molecular mechanisms associated with GBC, especially in patients of African ancestry. This study aimed to determine dysregulated proteins in South African GBC patients to identify potential mechanisms of the disease progression and plausible biomarkers. Tissues (27 GBC, 13 Gallstone disease, and 5 normal tissues) and blood plasma (54 GBC and 73 Benign biliary pathology) were obtained from consenting patients. Protein extraction was performed on all tissues and liquid chromatography-mass spectrometry was used for proteomic profiling. A project-specific spectral library was built using the Pulsar search algorithm. Principal component and Spearman's rank correlation analyses were performed using PAST (V4.07b). Pathway and Network analyses were conducted using REACTOME (v3.7) and stringAPP (v1.7.0), respectively. In the tissue sample group, there were 62 and 194 dysregulated proteins in GBC compared to normal and gallstone groups, respectively. In the plasma group, there were 33 altered proteins in GBC compared to the benign biliary pathology group. We found 9 proteins (APOA1, APOA2, RET4, TTR, HEMO, HBB, HBA, PIGR, and APOE) to be commonly dysregulated in both tissue and plasma. Furthermore, a subset analysis demonstrated that 2 proteins, S100A8 and S100A9, were downregulated in GBC patients with GD history compared to those without. Pathway analysis showed that the dysregulated proteins in GBC patients were enriched in pathways involved in smooth muscle contraction, metabolism, ECM organization, and integrin cell surface interactions. The identified dysregulated proteins help in understanding GBC molecular mechanisms in our patient group. Furthermore, the alteration of specific proteins in both tissue and plasma samples suggests their potential utility as biomarkers of GBC in this sample cohort.
Sections du résumé
BACKGROUND
BACKGROUND
Gallbladder cancer (GBC) is a lethal cancer with a poor prognosis. The lack of specific and sensitive biomarkers results in delayed diagnosis with most patients presenting at late stages of the disease. Furthermore, there is little known about the molecular mechanisms associated with GBC, especially in patients of African ancestry. This study aimed to determine dysregulated proteins in South African GBC patients to identify potential mechanisms of the disease progression and plausible biomarkers.
METHODS
METHODS
Tissues (27 GBC, 13 Gallstone disease, and 5 normal tissues) and blood plasma (54 GBC and 73 Benign biliary pathology) were obtained from consenting patients. Protein extraction was performed on all tissues and liquid chromatography-mass spectrometry was used for proteomic profiling. A project-specific spectral library was built using the Pulsar search algorithm. Principal component and Spearman's rank correlation analyses were performed using PAST (V4.07b). Pathway and Network analyses were conducted using REACTOME (v3.7) and stringAPP (v1.7.0), respectively.
RESULTS
RESULTS
In the tissue sample group, there were 62 and 194 dysregulated proteins in GBC compared to normal and gallstone groups, respectively. In the plasma group, there were 33 altered proteins in GBC compared to the benign biliary pathology group. We found 9 proteins (APOA1, APOA2, RET4, TTR, HEMO, HBB, HBA, PIGR, and APOE) to be commonly dysregulated in both tissue and plasma. Furthermore, a subset analysis demonstrated that 2 proteins, S100A8 and S100A9, were downregulated in GBC patients with GD history compared to those without. Pathway analysis showed that the dysregulated proteins in GBC patients were enriched in pathways involved in smooth muscle contraction, metabolism, ECM organization, and integrin cell surface interactions.
CONCLUSION
CONCLUSIONS
The identified dysregulated proteins help in understanding GBC molecular mechanisms in our patient group. Furthermore, the alteration of specific proteins in both tissue and plasma samples suggests their potential utility as biomarkers of GBC in this sample cohort.
Identifiants
pubmed: 36855072
doi: 10.1186/s12014-023-09399-9
pii: 10.1186/s12014-023-09399-9
pmc: PMC9976386
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8Informations de copyright
© 2023. The Author(s).
Références
BMC Cancer. 2010 Oct 19;10:564
pubmed: 20955617
Antioxid Redox Signal. 2015 Nov 10;23(14):1144-70
pubmed: 26415143
Sci Rep. 2021 Dec 7;11(1):23554
pubmed: 34876625
BMC Cancer. 2017 Dec 04;17(1):817
pubmed: 29202799
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Gut. 2019 Jun;68(6):1024-1033
pubmed: 29954840
Curr Gastroenterol Rep. 2004 Apr;6(2):151-62
pubmed: 15191695
CA Cancer J Clin. 2001 Nov-Dec;51(6):349-64
pubmed: 11760569
Tumour Biol. 2016 Aug;37(8):10715-21
pubmed: 26873483
Pathol Oncol Res. 2016 Jul;22(3):483-92
pubmed: 26634853
Dig Dis Sci. 2015 May;60(5):1273-83
pubmed: 25487191
Surgery. 2022 Apr;171(4):855-858
pubmed: 35086733
Nat Biotechnol. 2014 Mar;32(3):223-6
pubmed: 24727771
Gynecol Obstet (Sunnyvale). 2013 Apr 29;Suppl 4:3
pubmed: 24466501
Cytokine. 2015 May;73(1):84-90
pubmed: 25743242
Clin Gastroenterol Hepatol. 2008 Aug;6(8):944-950.e3
pubmed: 18585976
PLoS One. 2020 Oct 13;15(10):e0240453
pubmed: 33048956
Ann Surg. 1987 Jun;205(6):641-8
pubmed: 3592806
J Proteome Res. 2019 Feb 1;18(2):623-632
pubmed: 30450911
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
IUBMB Life. 2005 Nov;57(11):749-59
pubmed: 16511968
Cancers (Basel). 2020 Dec 07;12(12):
pubmed: 33297469
N Am J Med Sci. 2012 Jul;4(7):293-9
pubmed: 22866265
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Clin Epidemiol. 2014 Mar 07;6:99-109
pubmed: 24634588
J Pediatr Hematol Oncol. 2015 May;37(4):245-51
pubmed: 25811750
Hepatobiliary Surg Nutr. 2014 Jun;3(3):126-39
pubmed: 25019074
Chin Clin Oncol. 2019 Aug;8(4):31
pubmed: 31484487
Pathol Res Pract. 2017 May;213(5):476-482
pubmed: 28285962
Cancer. 2021 Jul 1;127(13):2238-2250
pubmed: 33748947
Cancers (Basel). 2021 Feb 10;13(4):
pubmed: 33578820
Oncol Rep. 2011 Oct;26(4):853-9
pubmed: 21687958
Mol Cell Proteomics. 2012 Jun;11(6):O111.016717
pubmed: 22261725
Iran J Pathol. 2019 Spring;14(2):104-112
pubmed: 31528166
Nature. 2008 Apr 3;452(7187):571-9
pubmed: 18385731
Mol Syst Biol. 2018 Aug 13;14(8):e8126
pubmed: 30104418
Front Genet. 2018 Dec 13;9:650
pubmed: 30631342
Elife. 2017 Dec 19;6:
pubmed: 29256392
Mol Cell Proteomics. 2019 May;18(5):1027-1035
pubmed: 30833379
BMC Bioinformatics. 2017 Mar 2;18(1):142
pubmed: 28249561
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
World J Gastroenterol. 2014 Apr 14;20(14):4085-92
pubmed: 24744600
Cancer Lett. 2021 Sep 10;521:238-251
pubmed: 34506845
J Epidemiol Community Health. 2007 Sep;61(9):824-33
pubmed: 17699539
Int J Cancer. 2007 Aug 15;121(4):832-8
pubmed: 17450525
Semin Perinatol. 2011 Jun;35(3):121-6
pubmed: 21641484
Gastroenterology. 1996 Jan;110(1):251-7
pubmed: 8536864
Nat Commun. 2020 Oct 9;11(1):5120
pubmed: 33037194
EBioMedicine. 2020 Sep;59:102954
pubmed: 32818802
Biochim Biophys Acta. 2016 Apr;1865(2):245-54
pubmed: 26980625
J Clin Diagn Res. 2015 Jul;9(7):PC04-7
pubmed: 26393162
Clin Exp Pharmacol Physiol. 2000 Dec;27(12):951-5
pubmed: 11117230
Mol Biol Rep. 2020 Mar;47(3):2361-2369
pubmed: 32020429
World J Gastroenterol. 2014 May 14;20(18):5511-8
pubmed: 24833881
Front Immunol. 2018 Jun 11;9:1298
pubmed: 29942307
Clin Transl Med. 2021 Jun;11(6):e462
pubmed: 34185421
Nucleic Acids Res. 2021 Jan 8;49(D1):D394-D403
pubmed: 33290554
Cancer. 1992 Sep 15;70(6):1493-7
pubmed: 1516000
Future Oncol. 2012 Jan;8(1):55-71
pubmed: 22149035
Clin Exp Hepatol. 2019 May;5(2):93-102
pubmed: 31501784
Cell Syst. 2016 Mar 23;2(3):185-95
pubmed: 27135364
BMC Cancer. 2020 Aug 31;20(1):826
pubmed: 32867709
BMC Cancer. 2008 Jan 28;8:25
pubmed: 18226209
Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):1052-6
pubmed: 15184263
EMBO Rep. 2014 Dec;15(12):1243-53
pubmed: 25381661
Int J Cancer. 2008 May 15;122(10):2322-9
pubmed: 18076041
EMBO Mol Med. 2019 Nov 7;11(11):e10427
pubmed: 31566909
Br J Cancer. 2007 Dec 3;97(11):1577-82
pubmed: 18000509